Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice

Nature Biotechnology

Volumn 33, Issue 4, 2015, Pages 402-407

  Obenaus, Matthias ^a   Leitão, Catarina ^a,g   Leisegang, Matthias ^a   Chen, Xiaojing ^a   Gavvovidis, Ioannis ^a   Van Der Bruggen, Pierre ^b,c   Uckert, Wolfgang ^a,d   Schendel, Dolores J ^e   Blankenstein, Thomas ^a,f  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^c DE DUVE INSTITUTE   (Belgium)

^d HUMBOLDT UNIVERSITY   (Germany)

^e MediGene AG   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; ANTIGENS; CELL MEMBRANES; CELLS; CYTOLOGY; DISEASES; MAMMALS; TUMORS;

ANTITUMOR EFFECT; CELL THERAPY; HIGH AFFINITY; HUMAN LEUKOCYTE ANTIGEN; HUMAN T CELLS; MOUSE MODELS; T CELL RECEPTOR; THERAPEUTIC EFFECTS;

T-CELLS;

GAMMA INTERFERON; HLA A2 ANTIGEN; MELANOMA ANTIGEN 1; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TUMOR ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN BINDING;

ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CROSS REACTION; FIBROSARCOMA CELL; HLA SYSTEM; HUMAN; IN VIVO STUDY; LEUKOCYTE; LIMIT OF DETECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RECEPTOR AFFINITY; RECEPTOR BINDING; TESTIS CANCER; TUMOR IMMUNOLOGY; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BINDING SITE; DEVICES; FEMALE; IMMUNOASSAY; IMMUNOLOGY; MOLECULAR GENETICS; NEOPLASMS, EXPERIMENTAL; PROCEDURES; SPECIES DIFFERENCE; TUMOR CELL LINE;

MUS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, NEOPLASM; BINDING SITES; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOASSAY; IMMUNOTHERAPY, ADOPTIVE; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; RECEPTORS, ANTIGEN, T-CELL; SPECIES SPECIFICITY;

EID: 84926670819     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3147     Document Type: Article

References (30)

1. June, C.H. Adoptive T cell therapy for cancer in the clinic. J. Clin. Invest. 117, 1466-1476 (2007).
2. Theobald, M. et al. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med. 185, 833-841 (1997).
3. Li, L.-P. et al. Transgenic mice with a diverse human T cell antigen receptor repertoire. Nat. Med. 16, 1029-1034 (2010).
4. van der Bruggen, P. et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647 (1991).
5. Holler, P.D., Chlewicki, L.K. & Kranz, D.M. TCRs with high affinity for foreign pMHC show self-reactivity. Nat. Immunol. 4, 55-62 (2003).
6. Linette, G.P. et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122, 863-871 (2013).
7. Engels, B., Chervin, A.S., Sant, A.J., Kranz, D.M. & Schreiber, H. Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity. Mol. Ther. 20, 652-660 (2012).
8. Sadovnikova, E. & Stauss, H.J. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 93, 13114-13118 (1996).
9. Johnson, L.A. et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535-546 (2009).
10. Parkhurst, M.R. et al. Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin. Cancer Res. 15, 169-180 (2009).
11. Chinnasamy, N. et al. A TCR targeting the HLA-A∗0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J. Immunol. 186, 685-696 (2011).
12. Davis, J.L. et al. Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clin. Cancer Res. 16, 5852-5861 (2010).
13. Offringa, R. Antigen choice in adoptive T-cell therapy of cancer. Curr. Opin. Immunol. 21, 190-199 (2009).
14. Pascolo, S. et al. A MAGE-A1 HLA-A A∗0201 epitope identified by mass spectrometry. Cancer Res. 61, 4072-4077 (2001).
15. Toso, J.F. et al. MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation. Cancer Res. 56, 16-20 (1996).
16. Ottaviani, S., Zhang, Y., Boon, T. & van der Bruggen, P.A. MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells. Cancer Immunol. Immunother. 54, 1214-1220 (2005).
17. Huijbers, I.J. et al. Minimal tolerance to a tumor antigen encoded by a cancer-germline gene. J. Immunol. 188, 111-121 (2012).
18. Lee, E.-C. et al. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. Nat. Biotechnol. 32, 356-363 (2014).
19. Sommermeyer, D. & Uckert, W. Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells. J. Immunol. 184, 6223-6231 (2010).
20. Morgan, R.A. et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133-151 (2013).
21. Linnemann, C. et al. High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat. Med. 19, 1534-1541 (2013).
22. Chen, J.-L. et al. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J. Exp. Med. 201, 1243-1255 (2005).
23. Vierboom, M.P. et al. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med. 186, 695-704 (1997).
24. Scott-Browne, J.P., White, J., Kappler, J.W., Gapin, L. & Marrack, P. Germline-encoded amino acids in the alphabeta T-cell receptor control thymic selection. Nature 458, 1043-1046 (2009).
25. Aleksic, M. et al. Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur. J. Immunol. 42, 3174-3179 (2012).
26. Schmid, D.A. et al. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J. Immunol. 184, 4936-4946 (2010).
27. Wang, B. et al. A single peptide-MHC complex positively selects a diverse and specific CD8 T cell repertoire. Science 326, 871-874 (2009).
28. Birnbaum, M.E. et al. Deconstructing the peptide-MHC specificity of T cell recognition. Cell 157, 1073-1087 (2014).
29. Gotter, J., Brors, B., Hergenhahn, M. & Kyewski, B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J. Exp. Med. 199, 155-166 (2004).
30. Kammertoens, T. & Blankenstein, T. It's the peptide-MHC affinity, stupid. Cancer Cell 23, 429-431 (2013).